Effectiveness of Infliximab in Patients with Complex Regional Pain Syndrome: A Case Series

References

• Bruehl S. Complex regional pain syndrome. BMJ. 2015;351:h2730. doi:10.1136/bmj.h2730
   PubMed Web of Science ®Google Scholar
• Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain. 2003;103(1–2):199–207. doi:10.1016/s0304-3959(03)00065-4
   PubMed Web of Science ®Google Scholar
• de Mos M, de Bruijn AGJ, Huygen FJ, Dieleman JP, Stricker CBH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007;129(1):12–20. doi:10.1016/j.pain.2006.09.008
   PubMed Web of Science ®Google Scholar
• Harden NR, Bruehl S, Perez RS, et al. Validation of proposed diagnostic criteria (the “Budapest Criteria”) for complex regional pain syndrome. Pain. 2010;150(2):268–274. doi:10.1016/j.pain.2010.04.030
   PubMed Web of Science ®Google Scholar
• Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11(1):47–51. doi:10.1080/09629350210307
   PubMed Web of Science ®Google Scholar
• Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. PAIN. 2005;116(3):213–219. doi:10.1016/j.pain.2005.04.013
   PubMed Web of Science ®Google Scholar
• Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M. Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain. 2006;22(3):235–239. doi:10.1097/01.ajp.0000169669.70523.f0
   PubMed Web of Science ®Google Scholar
• Alexander GM, Peterlin BL, Perreault MJ, Grothusen JR, Schwartzman RJ. Changes in plasma cytokines and their soluble receptors in complex regional pain syndrome. J Pain. 2012;13(1):10–20. doi:10.1016/j.jpain.2011.10.003
   PubMed Web of Science ®Google Scholar
• Bruehl S, Warner DS. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010;113(3):713–725. doi:10.1097/aln.0b013e3181e3db38
   PubMed Web of Science ®Google Scholar
• Parkitny L, McAuley JH, Di Pietro F, et al. Inflammation in complex regional pain syndrome. A Systematic Review and Meta-Analysis. Neurology. 2013;80(1):106–117. doi:10.1212/wnl.0b013e31827b1aa1
   PubMed Web of Science ®Google Scholar
• Bharwani KD, Dirckx M, Stronks DL, Dik WA, Schreurs MWJ, Huygen F. Elevated plasma levels of sIL-2R in complex regional pain syndrome: a pathogenic role for T-lymphocytes? Mediators Inflamm. 2017;2017:2764261. doi:10.1155/2017/2764261
   PubMed Web of Science ®Google Scholar
• van den Berg C, de Bree PN, Huygen F, Tiemensma J. Glucocorticoid treatment in patients with complex regional pain syndrome: a systematic review. Eur J Pain. 2022;26:2009–2035. doi:10.1002/ejp.2025
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426. doi:10.1002/art.21984
   PubMed Web of Science ®Google Scholar
• Dirckx M, Schreurs MW, de Mos M, Stronks DL, Huygen FJ. The prevalence of autoantibodies in complex regional pain syndrome type I. Mediators Inflamm. 2015;2015:718201. doi:10.1155/2015/718201
   PubMed Web of Science ®Google Scholar
• Radner H, Aletaha D. Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr. 2015;165(1–2):3–9. doi:10.1007/s10354-015-0344-y
   PubMed Web of Science ®Google Scholar
• Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59(6):1341–1359. doi:10.2165/00003495-200059060-00010
   PubMed Web of Science ®Google Scholar
• Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage. 2004;27(2):101–103. doi:10.1016/j.jpainsymman.2003.12.006
   PubMed Web of Science ®Google Scholar
• Dirckx M, Groeneweg G, Wesseldijk F, Stronks DL, Huygen FJ. Report of a preliminary discontinued double-blind, randomized, placebo-controlled trial of the anti-TNF-α chimeric monoclonal antibody infliximab in complex regional pain syndrome. Pain Pract. 2013;13(8):633–640. doi:10.1111/papr.12078
   PubMed Web of Science ®Google Scholar
• EU General Data Protection Regulation (GDPR). Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), OJ 2016 L 119/1. 2016.
   Google Scholar
• Summary of product characteristics European Medicines Agency; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf. Accessed December 20, 2022.
   Google Scholar
• Harden NR, Bruehl S, Perez R, et al. Development of a severity score for CRPS. Pain. 2010;151(3):870–876. doi:10.1016/j.pain.2010.09.031
   PubMed Web of Science ®Google Scholar
• Fischer D, Stewart AL, Bloch DA, Lorig K, Laurent D, Holman H. Capturing the patient’s view of change as a clinical outcome measure. JAMA. 1999;282(12):1157–1162. doi:10.1001/jama.282.12.1157
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. PAIN. 2005;113(1):9–19. doi:10.1016/j.pain.2004.09.012
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Sandler I, Treister R, Suzan E, Haddad M. Anti tumor necrosis factor - alpha adalimumab for complex regional pain syndrome type 1 (CRPS-I): a case series. Pain Pract. 2013;13(8):649–656. doi:10.1111/papr.12070
   PubMed Web of Science ®Google Scholar
• Bernateck M, Rolke R, Birklein F, Treede RD, Fink M, Karst M. Successful intravenous regional block with low-dose tumor necrosis factor-alpha antibody infliximab for treatment of complex regional pain syndrome 1. Anesth Analg. 2007;105(4):1148–51, table of contents. doi:10.1213/01.ane.0000278867.24601.a0
   PubMed Web of Science ®Google Scholar
• Dirckx M, Stronks DL, van Bodegraven-Hof EA, Wesseldijk F, Groeneweg JG, Huygen FJ. Inflammation in cold complex regional pain syndrome. Acta Anaesthesiol Scand. 2015;59(6):733–739. doi:10.1111/aas.12465
   PubMed Web of Science ®Google Scholar
• Lenz M, Üçeyler N, Frettlöh J, et al. Local cytokine changes in complex regional pain syndrome type I (CRPS I) resolve after 6 months. PAIN. 2013;154(10):2142–2149. doi:10.1016/j.pain.2013.06.039
   PubMed Web of Science ®Google Scholar
• Birklein F, Ajit SK, Goebel A, Perez R, Sommer C. Complex regional pain syndrome - phenotypic characteristics and potential biomarkers. Nat Rev Neurol. 2018;14(5):272–284. doi:10.1038/nrneurol.2018.20
   PubMed Web of Science ®Google Scholar
• Bank PJ, van Rooijen DE, Marinus J, Reilmann R, van Hilten JJ. Force modulation deficits in complex regional pain syndrome: a potential role for impaired sense of force production. Eur J Pain. 2014;18(7):1013–1023. doi:10.1002/j.1532-2149.2013.00446.x
   PubMed Web of Science ®Google Scholar
• Schattschneider J, Hartung K, Stengel M, et al. Endothelial dysfunction in cold type complex regional pain syndrome. Neurology. 2006;67(4):673–675. doi:10.1212/01.wnl.0000229931.40631.31
   PubMed Web of Science ®Google Scholar
• Maihöfner C, Handwerker HO, Neundörfer B, Birklein F. Patterns of cortical reorganization in complex regional pain syndrome. Neurology. 2003;61(12):1707. doi:10.1212/01.wnl.0000098939.02752.8e
   PubMed Web of Science ®Google Scholar
• Marinus J, Moseley GL, Birklein F, et al. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011;10(7):637–648. doi:10.1016/s1474-4422(11)70106-5
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Seitz T, Tillack-Schreiber C, Lange S, Waggershauser C, Ochsenkühn T. Early start of infliximab in Crohn’s disease increases rates of endoscopic remission and decreases stenosis formation: experiences from a single center cohort. Crohns Colitis. 2021;3(3). doi:10.1093/crocol/otab060
   PubMedGoogle Scholar
• Ott S, Maihöfner C. Signs and symptoms in 1043 patients with complex regional pain syndrome. J Pain. 2018;19(6):599–611. doi:10.1016/j.jpain.2018.01.004
   PubMed Web of Science ®Google Scholar
• Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702–708. doi:10.1016/j.jaad.2019.05.022
   PubMed Web of Science ®Google Scholar
• Alten R, van den Bosch F. Dose optimization of infliximab in patients with rheumatoid arthritis. Int J Rheum Dis. 2014;17(1):5–18. doi:10.1111/1756-185X.12202
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther. 2010;12(3):R77. doi:10.1186/ar2997
   PubMed Web of Science ®Google Scholar
• Kopp TI, Delcoigne B, Arkema EV, et al. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Ann Rheum Dis. 2020;79(5):566. doi:10.1136/annrheumdis-2019-216693
   PubMed Web of Science ®Google Scholar
• Gharib MH, AlKahlout MA, Garcia Canibano B, Theophiel Deleu D, Malallah AlEssa H, AlEmadi S. Demyelinating neurological adverse events following the use of anti-TNF-α agents: a double-edged sword. Case Rep Neurol Med. 2022;2022:3784938. doi:10.1155/2022/3784938
   PubMed Web of Science ®Google Scholar
• Andreadou E, Kemanetzoglou E, Brokalaki C, et al. Demyelinating disease following Anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med. 2013;2013:671935. doi:10.1155/2013/671935
   PubMedGoogle Scholar
• Goebel A, Baranowski A, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann Intern Med. 2010;152(3):152–158. doi:10.7326/0003-4819-152-3-201002020-00006
   PubMed Web of Science ®Google Scholar